

# United States Patent and Trademark Office

1

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/561,188	12/19/2005		Jordi Tormo I Blasco	5000-0143PUS1	3913	
2292	7590	10/04/2006		EXAMINER		
BIRCH ST		KOLASCH & BIF	PRYOR, ALTON NATHANIEL			
		A 22040-0747	ART UNIT	PAPER NUMBER		
	,			1616		

DATE MAILED: 10/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/561,188	I BLASCO ET AL.					
Office Action Summary	Examiner	Art Unit					
	Alton N. Pryor	1616					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
Responsive to communication(s) filed on <u>28 Au</u> This action is <b>FINAL</b> . 2b)⊠ This     Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro						
Disposition of Claims							
4) Claim(s) 1-19 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) 1,3-11,13,15-19 is/are rejected. 7) Claim(s) 2,12 and 14 is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers	vn from consideration. r election requirement.						
<ul> <li>9) The specification is objected to by the Examiner.</li> <li>10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).</li> <li>11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.</li> </ul>							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 12/16/05.	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6)  Other:	ate					

Art Unit: 1616

#### **DETAILED ACTION**

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1.3-11.13.15-17.19 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for synergistic fungicidal mixtures comprising a triazolopyrimidine derivative of formula I and an acryloylmorpholide of formula II, wherein the weight ratio of formula I to formula II is from 100:1 to 1:100. Note applicant provides synergistic results for mixtures comprising the two active compounds in said ratio. In addition applicant is enabled for a method comprising applying the composition comprising the triazolopyrimidine derivative of formula I and the acryloylmorpholide of formula II to fungi. However, the specification does not reasonably provide enablement for synergistic fungicide mixtures comprising the two actives outside of the weight ratio specified. It would place undue burden on an artisan in the field to make and test numerous ratios outside of the ratio recited above and in the claims, without the assurance of obtaining synergism. In addition, the specification is not enabling for applying the triazolopyrimidine of formula I and acryloylmorpholide of formula II to fungi separately or successively to fungi for synergism. To make a test the application of formula I and formula II to the fungi separately or successively for synergism would create undue burden on artisan in the field. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly

Application/Control Number: 10/561,188

Art Unit: 1616

connected, to make and use the invention commensurate in scope with these claims. Note claims 1-12 are rejected under 35 USC 112, 2<sup>nd</sup> paragraph below for not being complete in that the structures of formula I and II are not included in the claims. The 35 USC 112, 1<sup>st</sup> paragraph rejection above uses the description of formula I and formula II in the specification in order to reject instant claims 1,3-12.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 6-9,16,17 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 6-9,16,17 recites the limitation "applied ... separately, or in succession". In claim 1, from which the claims depend, is to a fungicidal mixture. A mixture does not allow for separate or successive application of ingredients contained therein. There is insufficient antecedent basis for this limitation in the claim.

Claims 18,19 provides for the use of a fungicidal composition, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 18,19 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under

Application/Control Number: 10/561,188 Page 4

Art Unit: 1616

35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

#### Claim Objection

Claims 2,12,14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicant provides synergistic results for fungicidal mixtures comprising a triazolopyrimidine derivative of formula I and an acryloylmorpholide of formula II, wherein the weight ratio of formula I to formula II is from 100:1 to 1:100.

### **Telephonic Inquiry**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 571-272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/561,188 Page 5

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Alton Pryor

Primary Examiner

AU 1616